All In Biotech

Drug Trial Radar · NCT04153149

HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

HELIOS-B: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 655 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

655

Actual

Start

Nov 26, 2019

Primary completion

May 8, 2024

Study completion Jan 13, 2027

Sponsor

Lead sponsor
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
Sponsor type
Industry
First posted
Nov 6, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy and safety of vutrisiran 25 mg administered subcutaneously (SC) once every 3 months (q3M) compared to placebo in participants with ATTR amyloidosis with cardiomyopathy.

Conditions

  • Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

Interventions

  • VutrisiranDrug

    Vutrisiran will be administered by SC injection.

  • Sterile Normal Saline (0.9% NaCl)Drug

    Sterile normal saline (0.9% NaCl) will be administered by SC injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular (CV) Events (CV Hospitalizations and Urgent Heart Failure [HF] Visits) in the Overall PopulationTime frame: Up to Month 36
  2. Composite Endpoint of All-Cause Mortality and Recurrent CV Events (CV Hospitalizations and Urgent HF Visits) in the Vutrisiran Monotherapy SubgroupTime frame: Up to Month 36

Locations

121 sites in 33 countries. Site status is shown where the registry gives one.

  • Clinical Trial Site

    La Mesa, California

  • Clinical Trial Site

    Los Angeles, California

  • Clinical Trial Site

    Stanford, California

  • Clinical Trial Site

    Washington D.C., District of Columbia

  • Clinical Trial Site

    Gainesville, Georgia

  • Clinical Trial Site

    Chicago, Illinois

  • Clinical Trial Site

    Evanston, Illinois

  • Clinical Trial Site

    Boston, Massachusetts

  • Clinical Trial Site

    Boston, Massachusetts

  • Clinical Trial Site

    Rochester, Minnesota

  • Clinical Trial Site

    Manhasset, New York

  • Clinical Trial Site

    New York, New York

  • Clinical Trial Site

    Durham, North Carolina

  • Clinical Trial Site

    Cleveland, Ohio

  • Clinical Trial Site

    Allentown, Pennsylvania

  • Clinical Trial Site

    Philadelphia, Pennsylvania

  • Clinical Trial Site

    Houston, Texas

  • Clinical Trial Site

    Buenos Aires, Argentina

  • Clinical Trial Site

    Buenos Aires, Argentina

  • Clinical Trial Site

    Buenos Aires, Argentina

  • Clinical Trial Site

    Buenos Aires, Argentina

  • Clinical Trial Site

    Adelaide, Australia

  • Clinical Trial Site

    Darlinghurst, Australia

  • Clinical Trial Site

    Melbourne, Australia

  • Clinical Trial Site

    Northmead, Australia

  • Clinical Trial Site

    Woolloongabba, Australia

  • Clinical Trial Site

    Graz, Austria

  • Clinical Trial Site

    Vienna, Austria

  • Clinical Trial Site

    Vienna, Austria

  • Clinical Trial Site

    Brussels, Belgium

  • Clinical Trial Site

    Dendermonde, Belgium

  • Clinical Trial Site

    Ghent, Belgium

  • Clinical Trial Site

    Leuven, Belgium

  • Clinical Trial Site

    Québec, Canada

  • Clinical Trial Site

    Toronto, Canada

  • Clinical Trial Site

    Bogotá D.C., Colombia

  • Clinical Trial Site

    Zagreb, Croatia

  • Clinical Trial Site

    Olomouc, Czechia

  • Clinical Trial Site

    Prague, Czechia

  • Clinical Trial Site

    Aarhus N, Denmark

Showing 40 of 121 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.